An Overview of Targeting Legumain for Inhibiting Cancers

Author(s): Bandi D. Reddy, Narasimha M. Beeraka, CH. M. Kumari Chitturi, SubbaRao V. Madhunapantula*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 31 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Legumain (LGMN; EC: 3.4.22.34), an asparaginyl endopeptidase (AEP) or asparaginyl carboxypeptidase (ACP), is a member of the C13 family of cysteine proteases. Elevated expression of LGMN is reported not only in the tumor cells of breast, prostate, and liver but also in the macrophages of the tumor microenvironment. Hence, LGMN is considered as a key protein involved in the regulation of tumor angiogenesis, invasion, and metastasis. Targeting LGMN using siRNA or pharmacological agents and peptides was reported to reduce cancer cell proliferation in vitro and shrink tumor size in vivo. Moreover, expression of LGMN is significantly low in normal cells compared to tumor cells or tumor-associated macrophages (TAMs); hence, legumain can be used as a marker for tumor recognition and targeting. Therefore, approaches inhibiting LGMN expression or activity are more viable, less toxic, and help in developing the targeted therapeutics. However, to date, LGMN targeting strategies have not been well reported. In this review, an attempt was made to summarize articles pertaining to LGMN (a) structure and activity; (b) oncogenic nature; (c) pharmacological inhibitors; and (d) targeting approaches that inhibit tumor growth. Furthermore, a list of existing gaps in LGMN research is highlighted, which needs additional studies.

Keywords: Legumain, cancers, TAMs, metastasis, targeted therapies, DNA vaccines, miRNAs.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 31
Year: 2021
Published on: 24 November, 2020
Page: [3337 - 3348]
Pages: 12
DOI: 10.2174/1381612826666201125111625
Price: $65

Article Metrics

PDF: 293